Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of CimetrA in hospitalized adults with COVID-19
MOH_2021-03-04_009813Phase 3Not yet recruiting
- Sponsor
- Argent BioPharma
- Start
- Feb 2021
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CimetrA in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Argent BioPharma. Primary endpoint: Time to sustained clinical improvement. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
CimetrA
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2021-03-04_009813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-04_009813.